11,001 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by International Assets Investment Management LLC

International Assets Investment Management LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 11,001 shares of the biopharmaceutical company’s stock, valued at approximately $30,260,000.

A number of other large investors also recently added to or reduced their stakes in the business. Lecap Asset Management Ltd. purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth $669,000. Signaturefd LLC raised its position in Alnylam Pharmaceuticals by 34.1% in the 3rd quarter. Signaturefd LLC now owns 1,854 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 471 shares during the period. Allspring Global Investments Holdings LLC raised its position in Alnylam Pharmaceuticals by 62.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 161 shares during the period. Essex LLC purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $217,000. Finally, Friedenthal Financial purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $51,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $286.91 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company’s 50-day simple moving average is $274.68 and its 200 day simple moving average is $223.34. The firm has a market capitalization of $36.29 billion, a P/E ratio of -107.06 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same period in the previous year, the firm earned ($2.21) EPS. The company’s revenue was up 107.0% on a year-over-year basis. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares of the company’s stock, valued at approximately $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares of the company’s stock, valued at approximately $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,829,070. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,398 shares of company stock valued at $13,595,460. Insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on ALNY shares. Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a research report on Friday, July 12th. Scotiabank started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $305.00 price objective on the stock. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $198.00 to $370.00 in a research report on Friday, August 16th. JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Finally, Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Six analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $290.86.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.